Novartis reveals five-year efficacy data for Kesimpta
Patients treated with Kesimpta experienced considerable decreases in relapse rates
Read Moreby John Pinching | Jul 6, 2023 | News | 0
Patients treated with Kesimpta experienced considerable decreases in relapse rates
Read Moreby John Pinching | Mar 2, 2022 | News | 0
MS patients given boost by results of study into Kesimpta – a self-administered treatment with potential to improve lives
Read Moreby Lucy Parsons | Jul 13, 2021 | News | 0
SMC was unable to accept Pfizer’s Vyndaqel for use in patients with transthyretin amyloidosis
Read Moreby Lucy Parsons | Jun 23, 2021 | News | 0
B-cell targeting therapy preserved patients’ IgG/IgM levels, with no increased risk of serious infections
Read Moreby Lucy Parsons | Apr 21, 2021 | News | 0
First self-administered, targeted B-cell therapy licensed for adults with relapsing forms of MS
Read Moreby Selina McKee | Apr 8, 2021 | News | 0
Kesimpta is the first self-administered B-cell therapy for patients with relapsing forms of multiple sclerosis
Read Moreby Lucy Parsons | Feb 1, 2021 | News | 0
Bumper meeting saw 13 new medicines recommended for approval
Read Moreby Selina McKee | Aug 24, 2020 | News | 0
The study assessed investigational immunotherapy spartalizumab (PDR001) in combination with targeted therapies Tafinlar and Mekinist
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
